DDInter222 DDInter534
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib. Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic
A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of gamma-aminobutyric acid activity. It is used in the treatment of severe anxiety disorders, as a hypnotic in the short-term management of insomnia, as a sedative and premedicant, as an anticonvulsant, and in the management of alcohol withdrawal syndrome. (From Martindale, The Extra Pharmacopoeia, 30th ed, p589) Given diazepam's storied history as a commonly used and effective medication for a variety of indications, contemporary advancements in the formulation and administration of the agent include the development and US FDA approval of an auto-injectable formulation for the rapid treatment of uncontrolled seizures in 2015-2016 . Combining diazepam, a proven effective therapy for acute repetitive seizures, with an auto-injector designed for subcutaneous administration that is quickly and easily administered offers the potential for complete, consistent drug absorption and rapid onset of effect . This current development is subsequently an important addition to the rescue therapy tool chest for patients with epilepsy .
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Quazepam
Quazepam {u} (Compound) resembles {v} (Compound) Diazepam
Bortezomib {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Clozapine {u} (Compound) resembles {v} (Compound) Diazepam
Bortezomib {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Diazepam
Bortezomib {u} (Compound) causes {v} (Side Effect) Thirst
Thirst {u} (Side Effect) is caused by {v} (Compound) Diazepam
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Quazepam
Quazepam {u} (Compound) resembles {v} (Compound) Flunitrazepam
Flunitrazepam {u} (Compound) resembles {v} (Compound) Diazepam
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clobazam
Clobazam {u} (Compound) resembles {v} (Compound) Oxazepam
Oxazepam {u} (Compound) resembles {v} (Compound) Diazepam
Bortezomib {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Clozapine {u} (Compound) resembles {v} (Compound) Oxazepam
Oxazepam {u} (Compound) resembles {v} (Compound) Diazepam
Bortezomib {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Flurbiprofen
Flurbiprofen {u} (Compound) resembles {v} (Compound) Diazepam
Bortezomib {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Quazepam
Quazepam {u} (Compound) resembles {v} (Compound) Diazepam
Bortezomib {u} (Compound) causes {v} (Side Effect) Thirst
Thirst {u} (Side Effect) is caused by {v} (Compound) Clonazepam
Clonazepam {u} (Compound) resembles {v} (Compound) Diazepam
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Quazepam and Quazepam (Compound) resembles Diazepam (Compound)
Bortezomib may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) resembles Diazepam (Compound)
Bortezomib (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Diazepam (Compound)
Bortezomib (Compound) causes Thirst (Side Effect) and Thirst (Side Effect) is caused by Diazepam (Compound)
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Quazepam and Quazepam (Compound) resembles Flunitrazepam (Compound) and Flunitrazepam (Compound) resembles Diazepam (Compound)
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Clobazam and Clobazam (Compound) resembles Oxazepam (Compound) and Oxazepam (Compound) resembles Diazepam (Compound)
Bortezomib may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) resembles Oxazepam (Compound) and Oxazepam (Compound) resembles Diazepam (Compound)
Bortezomib (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Flurbiprofen (Compound) and Flurbiprofen (Compound) resembles Diazepam (Compound)
Bortezomib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Quazepam (Compound) and Quazepam (Compound) resembles Diazepam (Compound)
Bortezomib (Compound) causes Thirst (Side Effect) and Thirst (Side Effect) is caused by Clonazepam (Compound) and Clonazepam (Compound) resembles Diazepam (Compound)